Phillip Md Et Al Frost Acquires 55,000 Shares of Opko Health Inc. (OPK) Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 55,000 shares of the firm’s stock in a transaction on Friday, February 2nd. The stock was bought at an average price of $4.30 per share, for a total transaction of $236,500.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $13,196,489.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, January 31st, Phillip Md Et Al Frost purchased 65,000 shares of Opko Health stock. The stock was bought at an average price of $4.47 per share, for a total transaction of $290,550.00.
  • On Friday, January 26th, Phillip Md Et Al Frost purchased 55,000 shares of Opko Health stock. The stock was bought at an average price of $4.90 per share, for a total transaction of $269,500.00.
  • On Wednesday, January 24th, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The stock was bought at an average price of $4.89 per share, for a total transaction of $489,000.00.
  • On Monday, January 22nd, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The stock was bought at an average price of $4.40 per share, for a total transaction of $440,000.00.

Shares of Opko Health Inc. (NASDAQ:OPK) opened at $4.27 on Monday. The company has a current ratio of 1.66, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01. Opko Health Inc. has a 12-month low of $4.25 and a 12-month high of $8.92. The firm has a market cap of $2,380.00, a PE ratio of -22.37 and a beta of 1.42.

Opko Health (NASDAQ:OPK) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The business had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. During the same quarter last year, the firm posted ($0.03) earnings per share. Opko Health’s revenue was down 11.6% on a year-over-year basis. analysts anticipate that Opko Health Inc. will post -0.27 earnings per share for the current year.

Several institutional investors have recently modified their holdings of OPK. Schwab Charles Investment Management Inc. boosted its position in shares of Opko Health by 20.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 1,095,177 shares of the biotechnology company’s stock valued at $7,207,000 after acquiring an additional 189,438 shares in the last quarter. Prudential Financial Inc. boosted its position in shares of Opko Health by 6.1% during the 2nd quarter. Prudential Financial Inc. now owns 24,511 shares of the biotechnology company’s stock valued at $161,000 after acquiring an additional 1,400 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Opko Health by 18.6% during the 2nd quarter. Alliancebernstein L.P. now owns 213,324 shares of the biotechnology company’s stock valued at $1,404,000 after acquiring an additional 33,400 shares in the last quarter. Teachers Advisors LLC boosted its position in shares of Opko Health by 17.5% during the 2nd quarter. Teachers Advisors LLC now owns 476,222 shares of the biotechnology company’s stock valued at $3,134,000 after acquiring an additional 70,971 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in shares of Opko Health by 4.5% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,016,286 shares of the biotechnology company’s stock valued at $6,687,000 after acquiring an additional 44,156 shares in the last quarter. Institutional investors and hedge funds own 22.94% of the company’s stock.

OPK has been the topic of several research analyst reports. Zacks Investment Research lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Cantor Fitzgerald set a $20.00 price target on shares of Opko Health and gave the stock a “buy” rating in a research report on Thursday, October 12th. Finally, BidaskClub lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 11th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $13.34.

COPYRIGHT VIOLATION NOTICE: “Phillip Md Et Al Frost Acquires 55,000 Shares of Opko Health Inc. (OPK) Stock” was originally reported by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thestockobserver.com/2018/02/05/phillip-md-et-al-frost-acquires-55000-shares-of-opko-health-inc-opk-stock.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply